Correlation between endoscopic and histological validated scoring indices in Crohn’s disease

Gong, Wenjing; Ke, Guo; Zheng, Tao; Miao, Fei; Xie, Hong‐Guang; Li, Weijie; Hong, Zhiwu; Ren, Huajian; Gu, Guosheng; Wang, Gefei; Wu, Xiuwen; Wang, Zhiming; Ren, Jianan; Li, Jieshou

doi:10.1016/j.dld.2019.01.010

Cited by 16 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though this score has not been much used in RCTs, its correlation with endoscopic activity scores has been measured. In particular, a recent study assessed the correlation between the Simple Endoscopic Score for Crohn's Disease (SES-CD) and the Naini and Cortina or the GHAS scores, 52 showing a very strong correlation (r > 0.8). And there was a significant correlation between the two histological scores.…”

Section: Robarts Histopathology Index (Rhi) 2017mentioning

confidence: 99%

“…And there was a significant correlation between the two histological scores. 52 Unlike most of the other indexes, this score has been partially validated. This allows an adequate accuracy, which is one of the strengths of the Naini and Cortina score.…”

Section: Robarts Histopathology Index (Rhi) 2017mentioning

confidence: 99%

“…Current evidence derives from studies using different scores to assess histological activity in IBD, thus do not allow for an overall view of the relevance of histology in CD and UC. 19,52 Despite these limitations, the role of microscopic inflammation in IBD, when appropriately assessed and scored by experienced pathologists, appears to be underestimated at present. 13 Because of the lack of an easy and universally used histological score for CD and UC, as well as the need for proper biopsy sampling and assessment by dedicated gastroenterologists and pathologists, further studies are required before microscopic activity can be considered a therapeutic target in IBD.…”

Section: Ileummentioning

confidence: 99%

See 2 more Smart Citations

Histological scores in inflammatory bowel disease

Neri

Mossa

Scucchi

et al. 2021

J of Digest Diseases

View full text Add to dashboard Cite

The role of histology in inflammatory bowel disease (IBD) has not yet been well defined. Endoscopic mucosal healing has been proposed as a predictor of the clinical course of IBD and it is indeed considered one of the main therapeutic targets. However, it does not necessarily imply histological healing. Histological remission has been reported to be associated with a better clinical outcome than endoscopic remission only in IBD patients. These observations support the view that histology plays a role as a potential therapeutic target in Crohn's disease and ulcerative colitis. Histological scores being able to quantify the degree of microscopic activity are needed for this purpose. In the era of biologics, indication for proper treatment may benefit from the assessment of clinical and endoscopic activity, as well as histological scores. Such scores may allow us to quantify the microscopic mucosal response to treatment and to define complete healing in IBD. A validated histological score in IBD may lead to the definition of microscopic activity in clinical practice, trials and investigational settings. Several attempts to develop such scores have been reported, but few are currently used and none is applied worldwide in clinical practice. The present review summarizes the main histological scores currently used for assessing IBD activity.

show abstract

Section: Robarts Histopathology Index (Rhi) 2017mentioning

confidence: 99%

Section: Robarts Histopathology Index (Rhi) 2017mentioning

confidence: 99%

Section: Ileummentioning

confidence: 99%

See 1 more Smart Citation

Histological scores in inflammatory bowel disease

Neri

Mossa

Scucchi

et al. 2021

J of Digest Diseases

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…Crohn's disease (CD), a lifelong disease caused by the interaction of genetic and environmental factors, can involve any part of the gastrointestinal tract, without an exact cause. [1][2][3] Even so, an abnormal mucosal inflammatory response is considered an essential component of the pathogenesis and progression of CD. 4,5 Matzinger first put forward the ''danger hypothesis'' two decades ago, in which immune responses were to identify danger signals regardless of whether they were endogenous or exogenous.…”

Section: Introductionmentioning

confidence: 99%

Preliminary exploration of the potential of spliceosome‐associated protein 130 for predicting disease severity in Crohn's disease

Gong

Zheng

et al. 2019

Annals of the New York Academy of Sciences

Self Cite

View full text Add to dashboard Cite

The role of spliceosome‐associated protein 130 (SAP130) in gut inflammation, particularly in Crohn's disease (CD), remains unclear. The aim of our study was to analyze correlations between serum SAP130 levels and CD severity, and to assess its predictive value for the clinical efficacy of exclusive enteral nutrition (EEN) in CD. Correlations between the SAP130 levels and CD severity were evaluated. SAP130 and its receptor Mincle (macrophage‐inducible C‐type lectin) in the colon tissue in active CD were measured. Furthermore, the serum SAP130 level was investigated as a predictor of clinical efficacy in patients treated with EEN. The serum SAP130 levels significantly increased in patients with active CD compared with patients in remission for CD (P < 0.001) and control individuals (P < 0.001), and they varied according to clinical activity and significantly correlated with disease severity. In parallel, the expression of both SAP130 and Mincle in colon tissue was elevated in active CD. Additionally, the serum SAP130 level declined in patients with active CD who achieved efficacy at week 8 after EEN therapy. This preliminary evidence shows that SAP130 might be a potential noninvasive biomarker that correlates well with CD severity and the clinical efficacy of EEN in CD.

show abstract

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

Gong

Zheng

et al. 2021

Clinical & Translational Med

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) has emerged a global disease and the ascending incidence and prevalence is accompanied by elevated morbidity, mortality, and substantial healthcare system costs. However, the current typical one‐size‐fits‐all therapeutic approach is suboptimal for a substantial proportion of patients due to the variability in the course of IBD and a considerable number of patients do not have positive response to the clinically approved drugs, so there is still a great, unmet demand for novel alternative therapeutic approaches. Spleen tyrosine kinase (Syk), a cytoplasmic nonreceptor protein tyrosine kinase, plays crucial roles in signal transduction and there are emerging data implicating that Syk participates in pathogenesis of several gut disorders, such as IBD. In this study, we observed the Syk expression in IBD patients and explored the effects of therapeutic Syk inhibition using small‐molecule Syk inhibitor piceatannol in bone marrow–derived macrophages (BMDMs). In addition, due to the poor bioavailability and pharmacokinetics of small‐molecule tyrosine kinase inhibitors and superiority of targeting nanoparticles‐based drug delivery system, we herein prepared piceatannol‐encapsulated poly(lactic‐co‐glycolic acid) nanoparticles that conjugated with chemokine C–C motif ligand 4 (P‐NPs‐C) and studied its therapeutic effects in vitro in BMDMs and in vivo in experimental colitis model. Our results indicated that in addition to alleviating colitis, oral administration of P‐NPs‐C promoted the restoration of intestinal barrier function and improved intestinal microflora dysbiosis, which represents a promising treatment for IBD.

show abstract

Correlation between endoscopic and histological validated scoring indices in Crohn’s disease

Cited by 16 publications

References 31 publications

Histological scores in inflammatory bowel disease

Histological scores in inflammatory bowel disease

Preliminary exploration of the potential of spliceosome‐associated protein 130 for predicting disease severity in Crohn's disease

CCL4‐mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease

Contact Info

Product

Resources

About